GSK enters research agreement with San Francisco incubator QB3@953

QB3@953, a San Francisco, USA-based incubator created by QB3, a University of California research institute and biotech accelerator, has announced an agreement with UK pharma company GlaxoSmithKline (LSE: GSK).

Together the companies will identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients. It formalizes an existing relationship between QB3@953 and GSK’s Discovery Partnerships with Academia team.

QB3@953 will work closely with GSK to identify innovators exploring targets with therapeutic potential and a defined clinical hypothesis, and will help facilitate collaborations between their researchers and GSK.